直接的サルコメア制御剤による心筋症治療の展望
Open Access
- 1 January 2019
- journal article
- Published by Japanese Circulation Society in Journal of JCS Cardiologists
- Vol. 28, 50-56
- https://doi.org/10.1253/jjcsc.28.0_50
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Impact of cardiac myosin light chain kinase gene mutation on development of dilated cardiomyopathyESC Heart Failure, 2019
- Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosinProceedings of the National Academy of Sciences of the United States of America, 2018
- Identification of MYLK3 mutations in familial dilated cardiomyopathyScientific Reports, 2017
- Lessons from a tarantula: new insights into myosin interacting-heads motif evolution and its implications on diseaseBiophysical Reviews, 2017
- Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypeseLife, 2017
- A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic CardiomyopathyPLOS ONE, 2016
- A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in miceScience, 2016
- Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosinJournal of Experimental Biology, 2016
- Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathyScience, 2015
- Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under loadArchives of Biochemistry and Biophysics, 2015